Tirzepatide (Mounjaro) Technically a dual GIP/GLP-1 receptor agonist, meaning it targets two incretin hormones rather than one
Plasma vitamin E was increased in the GSTM1-null group, while glutathione levels were increased in the GSTM1-present group, and blood vitamin C levels were increased in the GSTT1-present genotype, demonstrating the antioxidant impact of the grape juice differed based on the genotype of the participants
This pause matters pulling out early can let part of the dose leak back out
rhamnosus GG date back to clinical trials in 1987
It does mean clinicians still rely on overall risk, not LDL alone, when deciding whether medicine is worth the benefit.What is new in 2026 and what is not settledThree recent PubMed-indexed papers point in the same direction: lower LDL earlier may help some people, but the evidence is still evolving
If theres something we missed or something we could improve on, wed love to hear it